Re: Female sex
>Talk about impossible efficacy hurdles<
In all seriousness, one problem is that the FDA draws a distinction between FSAD (female sexual arousal disorder) and HSDD (hypoactive sexual desire disorder). HSDD supposedly means you don’t want to, while FSAD means you want to but just can’t. VVUS’ Alista failed at FSAD, but VVUS has a different drug in which they are still pursuing HSDD, as is PG, BPA, and various other companies.
However the distinction between inadequate sexual arousal and lack of libido is not a clean one in women, evidently. This is one reason the HSDD/FSAD indication/indications have been a black hole for various drug/biotech companies and will probably continue to be.
Market Data 
Markets 
AI
